Nuvation Bio Inc. (NUVB): Price and Financial Metrics


Nuvation Bio Inc. (NUVB): $3.53

0.06 (+1.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NUVB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NUVB Stock Price Chart Interactive Chart >

Price chart for NUVB

NUVB Price/Volume Stats

Current price $3.53 52-week high $14.50
Prev. close $3.47 52-week low $3.40
Day low $3.40 Volume 579,100
Day high $3.60 Avg. volume 864,209
50-day MA $4.88 Dividend yield N/A
200-day MA $7.22 Market Cap 773.28M

Nuvation Bio Inc. (NUVB) Company Bio


Nuvation Bio Inc. operates as a bio-pharmaceutical company. The Company focuses on developing oncology medicines that will improve patient lives by addressing drug resistance. Nuvation Bio serves patients worldwide.


NUVB Latest News Stream


Event/Time News Detail
Loading, please wait...

NUVB Latest Social Stream


Loading social stream, please wait...

View Full NUVB Social Stream

Latest NUVB News From Around the Web

Below are the latest news stories about Nuvation Bio Inc that investors may wish to consider to help them evaluate NUVB as an investment opportunity.

Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update. “In 2021, the Nuvation Bio team made significant progress for our lead cyclin-dependent kinase 2/4/6 inhibitor program in the clinic. NUV-422 received FDA Fast Track De

Business Wire | February 28, 2022

Nuvation Bio GAAP EPS of -$0.12 in-line

Nuvation Bio press release (NUVB): Q4 GAAP EPS of -$0.12 in-line.Strong balance sheet with cash, cash equivalents and marketable securities of $765.4 million as of December 31, 2021.

Seeking Alpha | February 28, 2022

Banks - Nuvation Bio Inc. Shares Purchased by Citigroup Inc

Citigroup Inc. boosted its position in Nuvation Bio Inc. by 104.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned…

Business Mag | February 17, 2022

Fund - Nuvation Bio Inc. Shares Purchased by Citigroup Inc

Citigroup Inc. boosted its position in Nuvation Bio Inc. by 104.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned…

Business Mag | February 17, 2022

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.

Yahoo | January 21, 2022

Read More 'NUVB' Stories Here

NUVB Price Returns

1-mo -26.92%
3-mo -33.77%
6-mo -60.38%
1-year -75.18%
3-year N/A
5-year N/A
YTD -58.47%
2021 -27.35%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6893 seconds.